Movement Alert｜Akeso Bio Rises 6.3% in Regular Trading, Biotech Sector Rally and AI Drug Platform Progress Fuel Rebound

Market Focus07-02

On July 2, Akeso Bio rose 6.3% in regular trading, trading at HK$95.45/share, with turnover of HK$191 million. The stock rebounded after an approximately 4% pullback in the prior session, supported by broad-based strength across the biotechnology sector.

On the news front, the company's Chief Scientific Officer recently disclosed progress on its AI-driven drug discovery platform, reinforcing long-term R&D efficiency expectations. The platform covers the full antibody and nucleic acid drug development process, incorporating proprietary AI modules for high-precision structure prediction, immunogenicity assessment, and automated humanization, enabling end-to-end precision from sequence design to clinical stage.

Within the Biotechnology sector, peers rallied in tandem: 3SBIO up 10.54%, SKB Bio up 7.70%, Remegen up 7.67%, Innovent Bio up 3.52%, and BeiGene up 2.17%, reflecting strong sector beta that amplified the individual stock rebound following a cumulative drawdown exceeding 30% from its post-ASCO highs in early June.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128469000?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128469000","market":"us","top_or_hot":-1,"title":"Movement Alert｜Akeso Bio Rises 6.3% in Regular Trading, Biotech Sector Rally and AI Drug Platform Progress Fuel Rebound","media":"Market Focus","content":"<p><p>On July 2, Akeso Bio rose 6.3% in regular trading, trading at HK$95.45/share, with turnover of HK$191 million. The stock rebounded after an approximately 4% pullback in the prior session, supported by broad-based strength across the biotechnology sector.</p><p>On the news front, the company's Chief Scientific Officer recently disclosed progress on its AI-driven drug discovery platform, reinforcing long-term R&D efficiency expectations. The platform covers the full antibody and nucleic acid drug development process, incorporating proprietary AI modules for high-precision structure prediction, immunogenicity assessment, and automated humanization, enabling end-to-end precision from sequence design to clinical stage.</p><p>Within the Biotechnology sector, peers rallied in tandem: 3SBIO up 10.54%, SKB Bio up 7.70%, Remegen up 7.67%, Innovent Bio up 3.52%, and BeiGene up 2.17%, reflecting strong sector beta that amplified the individual stock rebound following a cumulative drawdown exceeding 30% from its post-ASCO highs in early June.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Bio Rises 6.3% in Regular Trading, Biotech Sector Rally and AI Drug Platform Progress Fuel Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Bio Rises 6.3% in Regular Trading, Biotech Sector Rally and AI Drug Platform Progress Fuel Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-02 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 2, Akeso Bio rose 6.3% in regular trading, trading at HK$95.45/share, with turnover of HK$191 million. The stock rebounded after an approximately 4% pullback in the prior session, supported by broad-based strength across the biotechnology sector.</p><p>On the news front, the company's Chief Scientific Officer recently disclosed progress on its AI-driven drug discovery platform, reinforcing long-term R&D efficiency expectations. The platform covers the full antibody and nucleic acid drug development process, incorporating proprietary AI modules for high-precision structure prediction, immunogenicity assessment, and automated humanization, enabling end-to-end precision from sequence design to clinical stage.</p><p>Within the Biotechnology sector, peers rallied in tandem: 3SBIO up 10.54%, SKB Bio up 7.70%, Remegen up 7.67%, Innovent Bio up 3.52%, and BeiGene up 2.17%, reflecting strong sector beta that amplified the individual stock rebound following a cumulative drawdown exceeding 30% from its post-ASCO highs in early June.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1128469000","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128469000","pubTimestamp":1782955992,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 2, Akeso Bio rose 6.3% in regular trading, trading at HK$95.45/share, with turnover of HK$191 million. The stock rebounded after an approximately 4% pullback in the prior session, supported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"动向提示|康方生物常规交易涨6.3%生物科技板块反弹AI药物平台进展助推反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On July 2, Akeso Bio rose 6.3% in regular trading, trading at HK$95.45/share, with turnover of HK$191 million. The stock rebounded after an approximately 4% pullback in the prior session, supported by broad-based strength across the biotechnology sector.On the news front, the company's Chief Scientific Officer recently disclosed progress on its AI-driven drug discovery platform, reinforcing long-term R&D efficiency expectations. The platform covers the full antibody and nucleic acid drug development process, incorporating proprietary AI modules for high-precision structure prediction, immunogenicity assessment, and automated humanization, enabling end-to-end precision from sequence design to clinical stage.Within the Biotechnology sector, peers rallied in tandem: 3SBIO up 10.54%, SKB Bio up 7.70%, Remegen up 7.67%, Innovent Bio up 3.52%, and BeiGene up 2.17%, reflecting strong sector beta that amplified the individual stock rebound following a cumulative drawdown exceeding 30% from its post-ASCO highs in early June.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128469000","isCrawlerRequest":true}